Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studies-Reference-Cited by-同舟云学术

Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studies

Published:2020-06-11 Issue:10 Volume:40 Page:2385-2393
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver Int

Author:

Yao Betty B.¹,Fredrick Linda M.¹,Schnell Gretja¹,Kowdley Kris V.²,Kwo Paul Y.³,Poordad Fred⁴,Nguyen Kinh⁵,Lee Samuel S.⁶,George Christophe⁷,Wong Florence⁸^ORCID,Gane Edward⁹^ORCID,Abergel Armand¹⁰,Spearman Catherine W.¹¹,Nguyen Tuan¹²,Hung Le Manh¹³,Pham Thuy TT.¹⁴,Mensa Federico¹,Asselah Tarik¹⁵^ORCID

Affiliation:

1. AbbVie Inc North Chicago IL USA

2. Elson S. Floyd College of MedicineWashington State University Spokane WA USA

3. Stanford University School of Medicine Palo Alto CA USA

4. The Texas Liver InstituteUniversity of Texas Health San Antonio TX USA

5. National Hospital for Tropical Diseases Hanoi Vietnam

6. University of Calgary Calgary AB Canada

7. AZ Groeninge Campus Kennedylaan Kortrijk Belgium

8. Toronto General HospitalUniversity of Toronto Toronto ON Canada

9. Auckland Clinical Studies Auckland New Zealand

10. Centre Hospitalier Universitaire Estaing Clermont Ferrand France

11. Division of Hepatology Department of Medicine Faculty of Health Sciences University of Cape Town and Groote Schuur Hospital Cape Town South Africa

12. Alvarado Hospital Medical Center San Diego CA USA

13. Hospital for Tropical Diseases Ho Chi Minh Vietnam

14. Hoa Hao Medic Company Ltd Ho Chi Minh Vietnam

15. Department of Hepatology Centre de Recherche sur l’InflammationINSERM UMR 1149Université Paris DiderotAP‐HP Hôpital Beaujon Clichy France

Funder

AbbVie

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/liv.14535